Dr Reddys Net Worth
Dr Reddys Net Worth Breakdown | RDY |
Dr Reddys Net Worth Analysis
Dr Reddys' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dr Reddys' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dr Reddys' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dr Reddys' net worth analysis. One common approach is to calculate Dr Reddys' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dr Reddys' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dr Reddys' net worth. This approach calculates the present value of Dr Reddys' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dr Reddys' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dr Reddys' net worth. This involves comparing Dr Reddys' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dr Reddys' net worth relative to its peers.
Enterprise Value |
|
To determine if Dr Reddys is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dr Reddys' net worth research are outlined below:
| Dr Reddys generated a negative expected return over the last 90 days | |
| Latest headline from gurufocus.com: Kraig Biocraft Laboratories Reports Record-Setting Recombinant Spider Silk Production in 2024 |
Dr Reddys Quarterly Good Will |
|
Dr Reddys uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dr Reddys Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dr Reddys' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Dr Reddys' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dr Reddys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dr Reddys Laboratories backward and forwards among themselves. Dr Reddys' institutional investor refers to the entity that pools money to purchase Dr Reddys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-09-30 | 500.7 K | Fisher Asset Management, Llc | 2024-09-30 | 491.3 K | Gqg Partners Llc | 2024-09-30 | 437 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 409.4 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 343.8 K | Jane Street Group Llc | 2024-06-30 | 291.8 K | Man Group Plc | 2024-09-30 | 208.5 K | Wellington Management Company Llp | 2024-09-30 | 168.5 K | Lazard Asset Management Llc | 2024-09-30 | 167.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.2 M | Robeco Institutional Asset Management Bv | 2024-09-30 | 2.1 M |
Follow Dr Reddys' market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 12.15 B.Market Cap |
|
Project Dr Reddys' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.16 | 0.11 | |
| Return On Capital Employed | 0.23 | 0.24 | |
| Return On Assets | 0.14 | 0.15 | |
| Return On Equity | 0.20 | 0.10 |
When accessing Dr Reddys' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dr Reddys' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dr Reddys' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Check Dr Reddys' Beneish M Score to see the likelihood of Dr Reddys' management manipulating its earnings.
Evaluate Dr Reddys' management efficiency
Dr Reddys Laboratories has Return on Asset of 0.104 % which means that on every $100 spent on assets, it made $0.104 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1927 %, implying that it generated $0.1927 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Dr Reddys' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.15 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 16.9 B in 2024, whereas Total Assets are likely to drop slightly above 214.9 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 337.21 | 527.34 | |
| Tangible Book Value Per Share | 287.69 | 392.73 | |
| Enterprise Value Over EBITDA | 11.93 | 12.52 | |
| Price Book Value Ratio | 3.71 | 3.89 | |
| Enterprise Value Multiple | 11.93 | 12.52 | |
| Price Fair Value | 3.71 | 3.89 | |
| Enterprise Value | 1.1 T | 1.1 T |
Management at Dr Reddys Laboratories focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 3.3921 | Revenue 299.9 B | Quarterly Revenue Growth 0.165 | Revenue Per Share 60.1437 | Return On Equity 0.1927 |
Dr Reddys Corporate Filings
6K | 6th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 23rd of October 2024 Other Reports | ViewVerify |
Dr Reddys Earnings per Share Projection vs Actual
Dr Reddys Corporate Directors
| Leo Puri | Non-Executive Independent Director | Profile | |
| Arunabha RayChaudhuri | Head Director | Profile | |
| Prasad Menon | Lead Non-Executive Independent Director | Profile | |
| Shikha Sharma | Non-Executive Independent Director | Profile |
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.